Patent ID: 7582641
Filing Date: 2009-09-01
Classification: A61K,A61P,C07D

Abstract:
1. A method of controlling, treating or reducing the advancement, severity or effects of a nosocomial or a non-nosocomial bacterial infection in a patient, wherein the bacterial infection is characterized by the presence of one or more of the following: Methicillin resistant Staphylococci, Fluoroquinolone resistant Staphylococci, Glycopepetide resistant Staphylococci, Macrolide-Lincosamide-Streptogramin resistant Staphylococci, Linezolid resistant Enterococci, Glycopepetide resistant Enterococci, β-lactam resistant Enterococci, Penicillin resistant Streptococci, Macrolide resistant Streptococci, Ketolide resistant Streptococci, Fluoroquinolone resistant Streptococci, β-lactam resistant Haemophilus , Fluoroquinolone resistant Haemophilus , Macrolide resistant Haemophilus , Macrolide resistant Mycoplasma , Isoniazid resistant Mycobacterium , Rifampin resistant Mycobacterium , or β-lactam resistant Moraxella , comprising the step of administering to said patient a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein: W is selected from CH or CF; X is selected from CH or CF; Z is O or NH; R y is 0 or 1; T is a straight or branched C each R′ is independently selected from hydrogen, C Ar is a 5-6 membered saturated ring having 1-2 heteroatoms independently selected from oxygen, nitrogen or sulfur, a 5 membered heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen or sulfur, a 6-membered heteroaryl ring having 1-3 nitrogens or a phenyl ring, wherein: R Ring A is a pyrimidine ring wherein: